Atossa Therapeutics Inc (ATOS) Stock Price, Quote & News

Company Profile

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas. The company was formerly known as Atossa Genetics Inc. and changed...

Industry: Biotechnology

Sector: Healthcare

Phone: 206 588 0256

Website: www.atossatherapeutics.com

Address:

448 NW Market Street, Suite 500, Seattle, United States

Bullishbruk Aug. 30 at 10:50 PM

$ATOS guys and girls — how’s Quayland these days? Where’s the resident manager, Mr. Bunny? Still shouting in CAPS and saying “I told you so”? I still maintain Endoxifen is a promising drug stuck with a terrible CEO. A decent scientist, maybe — zero ability to lead ATOS to the promised land.

0 · Reply

todn Aug. 30 at 9:58 PM

$ATOS ?????

0 · Reply

The_Real_Heisenberg Aug. 29 at 4:47 PM

$ATOS for anyone interested, we just got solid evidence that my protocol is potentially assisting in healing the DNA. We just had a user post his MRI results before and after. Astonishing to say the least. https://lowtoxinforum.com/threads/whatisagings-hg7-log.53751/post-1024952

0 · Reply

dcajic2 Aug. 27 at 6:00 PM

$ATOS how exactly will sharehodkers ever make money off this company. They need to raise many dollars to survive which then the stock will be diluted. No coming back from being under $1 since they have done two many reverse splits.

0 · Reply

TheSilentVoid Aug. 27 at 5:17 PM

$ATOS What are the chances that Quay gets his cake and gets to eat it too? NIAID Director and ATOS stock surge or buyout. Do they need to appoint a permanent director immediately or could they wait until the EOY?

1 · Reply

back2tfuture Aug. 27 at 10:47 AM

$ATOS ..Remember.. remember the month of September.

1 · Reply

Bunster Aug. 26 at 4:49 PM

$ATOS

0 · Reply

NotHopeJustFacts Aug. 26 at 3:02 PM

$ATOS Dr Quay cult is the best, this is trading at around 0.17 cents PRE Reverse Split (february this year) and yet nobody complains about fraud, praise the lord !!! LMAO

0 · Reply

Bunster Aug. 25 at 9:36 PM

$ATOS 18 pennies a share...LESS THEN 2 DIMES GIRLS

0 · Reply

JDAAT Aug. 25 at 4:26 PM

$ATOS Zero shares available for short

0 · Reply

Atossa Therapeutics reports Q2 EPS (95c) vs. (98c) last year

Aug 7, 2026, 8:45 AM EDT - 23 days ago

Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

Aug 7, 2026, 7:00 AM EDT - 23 days ago

Atossa Therapeutics Quarterly report: Q2 2026

Aug 7, 2026, 7:00 AM EDT - 23 days ago

Atossa Therapeutics Earnings release: Q2 2026

2026-07-30T17:05:56.000Z - 4 weeks ago

Atossa Therapeutics sees opportunities for (Z)-endoxifen beyond breast cancer

2026-07-30T17:05:28.000Z - 4 weeks ago

Meet Atossa Therapeutics: Fly Exclusive with CFO Mark Daniel

2026-07-28T12:36:10.000Z - 4 weeks ago

Atossa Therapeutics’ (Z)-endoxifen compounds show anti-breast cancer action

Jul 28, 2026, 8:30 AM EDT - 4 weeks ago

Atossa Therapeutics Announces Publication of Novel (Z)-Endoxifen-Related Compounds Demonstrating Potent Anti-Cancer Activity in ER-Positive Breast Cancer

Jul 21, 2026, 8:30 AM EDT - 5 weeks ago

Atossa Therapeutics Announces Presentation of Mechanism-Driven (Z)-Endoxifen Data in McCune-Albright Syndrome at AACR Special Conference on Rare Cancers

2026-07-07T12:15:16.000Z - 7 weeks ago

Atossa Therapeutics initiated with a Buy at Rodman & Renshaw

Jun 12, 2026, 5:30 PM EDT - 2 months ago

Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds

2026-06-11T12:07:04.000Z - 2 months ago

Atossa Therapeutics announces registered direct offering of up to $16.5M

2026-06-11T12:06:50.000Z - 2 months ago

Atossa Therapeutics announces $16.5M registered direct offering

Jun 11, 2026, 8:00 AM EDT - 2 months ago

Atossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds

May 27, 2026, 8:30 AM EDT - 3 months ago

Atossa Therapeutics Announces ASCO 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across ESR1 Mutations and Ongoing EVANGELINE Phase 2 Trial

May 20, 2026, 4:45 PM EDT - 3 months ago

Atossa Therapeutics Announces Acceptance of Manuscript Highlighting Utrophin-Modulation Potential of (Z)-Endoxifen in Duchenne Muscular Dystrophy

May 19, 2026, 4:00 PM EDT - 3 months ago

Atossa Therapeutics Transcript: Status update

May 14, 2026, 8:30 AM EDT - 3 months ago

Atossa Therapeutics to Host Virtual KOL Event Featuring Dr. Laura Esserman to Discuss Development of (Z)-Endoxifen in ER-Positive Breast Cancer

2026-05-08T16:29:20.000Z - 4 months ago

Atossa Therapeutics reports Q1 EPS ($1.11) vs. (78c) last year

May 8, 2026, 8:45 AM EDT - 4 months ago

Atossa Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

May 8, 2026, 7:00 AM EDT - 4 months ago

Atossa Therapeutics Quarterly report: Q1 2026

May 8, 2026, 7:00 AM EDT - 4 months ago

Atossa Therapeutics Earnings release: Q1 2026

2026-05-07T05:43:04.000Z - 4 months ago

Atossa Therapeutics’ Endoxifen shows breast cancer risk prevention in trial

May 6, 2026, 8:30 AM EDT - 4 months ago

Atossa Therapeutics Announces Publication of KARISMA Endoxifen Trial Demonstrating Significant Reduction in Mammographic Breast Density in Healthy Premenopausal Women

2026-05-04T13:09:59.000Z - 4 months ago

Atossa Therapeutics says FDA grants RPD to (Z)-endoxifen to treat MAS

May 4, 2026, 8:30 AM EDT - 4 months ago

Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for McCune-Albright Syndrome

Mar 30, 2026, 8:00 AM EDT - 5 months ago

Atossa Therapeutics Proxy statement: Proxy filing

2026-03-26T11:21:53.000Z - 5 months ago

Atossa Therapeutics target adjusted to $25 from $7 at H.C. Wainwright

2026-03-25T21:40:26.000Z - 5 months ago

Atossa Therapeutics reports 2025 EPS ($4.04), consensus ($3.91)

Mar 25, 2026, 5:30 PM EDT - 5 months ago

Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update

Mar 25, 2026, 7:00 AM EDT - 5 months ago

Atossa Therapeutics Earnings release: Q4 2025

Mar 25, 2026, 7:00 AM EDT - 5 months ago

Atossa Therapeutics Annual report: Q4 2025

Mar 20, 2026, 8:00 AM EDT - 5 months ago

Atossa Therapeutics Proxy statement: Proxy filing

2026-03-19T12:07:12.000Z - 5 months ago

Atossa Therapeutics announces addition of two biopharma executives to team

Mar 19, 2026, 8:00 AM EDT - 5 months ago

Atossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two Experienced Biopharma Executives

Mar 12, 2026, 8:00 AM EDT - 6 months ago

Atossa Therapeutics Presents Clinical Trial Update Highlighting (Z)-Endoxifen Research at the 2026 MDA Clinical & Scientific Conference

2026-02-12T14:20:21.000Z - 7 months ago

Atossa Therapeutics price target lowered to $10 from $35 at Craig-Hallum

Feb 11, 2026, 8:30 AM EST - 7 months ago

Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 Outlook

Feb 11, 2026, 6:00 AM EST - 7 months ago

Atossa Therapeutics Slides: Corporate presentation

Feb 5, 2026, 8:30 AM EST - 7 months ago

Atossa Therapeutics Maintains Strong Market Position for (Z)-Endoxifen for Duchenne Muscular Dystrophy as Congress Reauthorizes Priority Review Voucher Program

Jan 21, 2026, 9:05 AM EST - 7 months ago

Atossa Therapeutics' Founder and CEO Steven Quay, M.D., Ph.D. Named One of The Top 50 Healthcare Technology CEOs of 2025

Jan 16, 2026, 4:40 PM EST - 8 months ago

Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen for the Treatment of Duchenne Muscular Dystrophy

Jan 6, 2026, 8:15 AM EST - 8 months ago

Atossa Therapeutics Receives FDA "Study May Proceed" Letter for (Z)-Endoxifen Investigational New Drug Application for Metastatic Breast Cancer

Dec 22, 2025, 7:00 AM EST - 8 months ago

Atossa Therapeutics Proxy statement: Proxy Filing

Dec 17, 2025, 8:15 AM EST - 9 months ago

Atossa Therapeutics Wins 2025 Clinical Trials Arena Research and Development Excellence Award in Precision Endocrine Therapy Category

Dec 15, 2025, 8:00 AM EST - 9 months ago

Atossa Therapeutics Presents Four Clinical Trial Updates Highlighting (Z)-Endoxifen Research at the 2025 San Antonio Breast Cancer Symposium

Dec 12, 2025, 7:00 AM EST - 9 months ago

Atossa Therapeutics Proxy statement: Proxy Filing

Dec 11, 2025, 8:00 AM EST - 9 months ago

Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for Duchenne Muscular Dystrophy

Dec 9, 2025, 8:00 AM EST - 9 months ago

Atossa Therapeutics Announces Issuance of U.S. Patent Covering Enteric Oral (Z)-Endoxifen Formulations and Methods of Treating Patients Using (Z)-Endoxifen

Dec 4, 2025, 8:00 AM EST - 9 months ago

Atossa Therapeutics Details Accelerated FDA Strategy to Advance (Z)-Endoxifen Across Breast Cancer Continuum

Dec 2, 2025, 8:00 AM EST - 9 months ago

Insilico Medicine and Atossa Therapeutics Publish AI-Driven Study in Nature Scientific Reports Identifying (Z)-Endoxifen as a Potential Therapeutic Candidate for Glioblastoma

Nov 17, 2025, 9:07 AM EST - 10 months ago

Atossa Highlights Emerging Opportunity for (Z)-Endoxifen in Duchenne Muscular Dystrophy, Including Symptomatic Female Carriers, Following Peer-Reviewed Publication and Scientific Presentation

Nov 12, 2025, 8:30 AM EST - 10 months ago

Atossa Therapeutics Earnings release: Q3 2025

Nov 12, 2025, 8:30 AM EST - 10 months ago

Atossa Therapeutics Quarterly report: Q3 2025

Nov 12, 2025, 8:15 AM EST - 10 months ago

Atossa Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

Nov 6, 2025, 8:00 AM EST - 10 months ago

Atossa Therapeutics Announces Acceptance of Four Abstracts Highlighting (Z)-Endoxifen Research for Presentation at the 2025 San Antonio Breast Cancer Symposium

Oct 21, 2025, 8:00 AM EDT - 11 months ago

Atossa Therapeutics Highlights Progress in RECAST™ DCIS Platform Trial at Early Detection Research Conference; Laura Esserman, MD, MBA, to Discuss Active-Surveillance Strategy and Novel Endocrine Agents

Oct 15, 2025, 8:00 AM EDT - 11 months ago

Atossa Therapeutics to Present at the Maxim Growth Summit 2025

Oct 14, 2025, 8:00 AM EDT - 11 months ago

Atossa Appoints Mark Daniel, CPA, as Chief Financial Officer to Lead Finance, Systems, and Capital Strategy for Commercial Readiness

Oct 13, 2025, 8:00 AM EDT - 11 months ago

Atossa Advances Global Patent Strategy for Z-Endoxifen with New Protection in Israel and Ongoing Renewals

Oct 6, 2025, 8:00 AM EDT - 11 months ago

Atossa Therapeutics Streamlines EVANGELINE Breast Cancer Clinical Trial to Prioritize for 2026 NDA-Enabling Activities

Oct 1, 2025, 8:30 AM EDT - 11 months ago

Atossa Therapeutics Names Janet R. Rea, MSPH, as Senior Vice President, R&D to Accelerate (Z)-Endoxifen Toward Key Regulatory Milestones

Sep 17, 2025, 8:00 AM EDT - 1 year ago

Atossa Therapeutics Appoints CORE IR for Investor Relations, Shareholder Communications and Public Relations Services

Sep 8, 2025, 3:00 PM EDT - 1 year ago

Atossa Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Announces Regulatory Strategy Aimed at Accelerating Development of Low-Dose (Z)-Endoxifen for Breast Cancer Risk Reduction

Aug 28, 2025, 8:30 AM EDT - 1 year ago

Atossa Therapeutics CEO to Discuss Clinical Progress and Upcoming Milestones at 27th Annual H.C. Wainwright Global Investment Conference

Aug 20, 2025, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Selects PSI as Contract Research Organization for Pivotal Dose-Ranging Study of (Z)-Endoxifen in Metastatic Breast Cancer

Aug 12, 2025, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Corporate Update

Aug 12, 2025, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Quarterly report: Q2 2025

Aug 12, 2025, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Earnings release: Q2 2025

Jul 29, 2025, 7:45 AM EDT - 1 year ago

Atossa Therapeutics Announces Positive FDA Feedback, Advances Toward IND for (Z)-Endoxifen Clinical Program in ER+/HER2- Metastatic Breast Cancer

Jun 5, 2025, 8:10 AM EDT - 1 year ago

Atossa Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

Jun 2, 2025, 8:45 AM EDT - 1 year ago

Atossa Therapeutics to Present at the Jefferies Global Healthcare Conference

May 22, 2025, 4:15 PM EDT - 1 year ago

Atossa Therapeutics Transcript: Status Update

May 20, 2025, 9:00 AM EDT - 1 year ago

Join Atossa Therapeutics' Exclusive Live Investor Webinar and Q&A Session on May 22

May 14, 2025, 8:15 AM EDT - 1 year ago

Atossa Therapeutics Announces Full Results from I‑SPY 2 Endocrine‑Optimization Sub‑Study Evaluating Low‑Dose (Z)‑Endoxifen

May 13, 2025, 8:00 AM EDT - 1 year ago

Atossa Therapeutics Announces First Quarter 2025 Financial Results and Provides a Corporate Update

May 12, 2025, 6:00 PM EDT - 1 year ago

Atossa Therapeutics Earnings release: Q1 2025

May 12, 2025, 6:00 PM EDT - 1 year ago

Atossa Therapeutics Quarterly report: Q1 2025

Apr 30, 2025, 8:45 AM EDT - 1 year ago

Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,281,056, Including 58 Claims Covering Various Formulations for its (Z)-endoxifen Portfolio

Apr 29, 2025, 8:45 AM EDT - 1 year ago

Atossa Therapeutics Proposes Potentially Groundbreaking Study Aimed at Reducing Interval Breast Cancer in High-Risk Women at AACR 2025

Apr 22, 2025, 8:45 AM EDT - 1 year ago

Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,275,684, Further Strengthening (Z)-endoxifen Portfolio

Apr 10, 2025, 8:00 AM EDT - 1 year ago

Nona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies for Breast Cancer

Mar 26, 2025, 8:00 AM EDT - 1 year ago

Atossa Therapeutics Proxy statement: Proxy Filing

Mar 25, 2025, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Earnings Call Transcript: Q4 2024

Mar 25, 2025, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Earnings release: Q4 2024

Mar 25, 2025, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Annual report: Q4 2024

Mar 25, 2025, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Slides: Q4 2024

Mar 25, 2025, 8:00 AM EDT - 1 year ago

Atossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update

Mar 20, 2025, 9:13 AM EDT - 1 year ago

Atossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

Bullishbruk Aug. 30 at 10:50 PM

0 · Reply

todn Aug. 30 at 9:58 PM

$ATOS ?????

0 · Reply

The_Real_Heisenberg Aug. 29 at 4:47 PM

0 · Reply

dcajic2 Aug. 27 at 6:00 PM

0 · Reply

TheSilentVoid Aug. 27 at 5:17 PM

1 · Reply

back2tfuture Aug. 27 at 10:47 AM

$ATOS ..Remember.. remember the month of September.

1 · Reply

Bunster Aug. 26 at 4:49 PM

$ATOS

0 · Reply

NotHopeJustFacts Aug. 26 at 3:02 PM

$ATOS Dr Quay cult is the best, this is trading at around 0.17 cents PRE Reverse Split (february this year) and yet nobody complains about fraud, praise the lord !!! LMAO

0 · Reply

Bunster Aug. 25 at 9:36 PM

$ATOS 18 pennies a share...LESS THEN 2 DIMES GIRLS

0 · Reply

JDAAT Aug. 25 at 4:26 PM

$ATOS Zero shares available for short

0 · Reply

dcajic2 Aug. 25 at 1:53 PM

$ATOS This is still an early stage company that needs mega bucks to survive. Any big injection of cash is going to bring the stock below $1 and then off the market. Volume is super low today.

0 · Reply

dcajic2 Aug. 25 at 1:52 PM

$ATOS how can people continue to say bullish year after year.

0 · Reply

Kittyc803 Aug. 25 at 1:31 PM

$ATOS

0 · Reply

Richmonddawg Aug. 25 at 1:13 PM

$ATOS

0 · Reply

DCalcote Aug. 25 at 12:49 PM

$ATOS ...

0 · Reply

dcajic2 Aug. 25 at 11:38 AM

$ATOS time to short again. How exactly will they survive. Still a company stuck In phase 2 mode. They still need to do a much bigger phase 2 study. Running out of money fast. Any injection of cash will dilute the stock significantly.

0 · Reply

Bunster Aug. 25 at 9:54 AM

$ATOS prime is feeling better today so lets do this. Prime has made some internet friends from this mb even though they were bulls and i was not. MANY Smart folks contributing and making this mb back in the day very good./ We were owners of a metabolite drug that was to fight one of the worst diseases out there. BC MVP ,WITH HIS SKILLS AND DETERMINATION LEAD NOT ONE, BUT 2 SITDOWNS Q AND A WITH KYLE FOR THE BENEFIT OF US. The mayor has been a stalwart and has brought all the bulls together like no other. When goetz was announced to lead evangeline mvp AND I WERE SMILING FROM HEAD TO TOE.

0 · Reply

Bunster Aug. 25 at 9:27 AM

$ATOS primes update.looks like day is getting closer to new ceo.Who will ever forget stevies boy in his labcoat pic above annies bed on the wall. Mr ripley one of the handsomest cats ever created, stealthily creeps to the wall , jumps up tears the pic down and drags it and puts it inside his litter box.

0 · Reply

Michaeljin_101 Aug. 24 at 8:01 PM

$ATOS Silence may be golden, but even the noblest of men must eventually break it—if only with a fart. A humble reminder that no one escapes biology.

0 · Reply

Chalutz Aug. 24 at 3:06 AM

$ATOS If Mayo Clinic did why not just post a link to it?

4 · Reply

Bunster Aug. 23 at 3:57 PM

$ATOS

0 · Reply

Bunster Aug. 23 at 1:34 PM

$ATOS

0 · Reply

Market Cap	25.75M
Revenue (ttm)	0.00
Net Income (ttm)	-34.77M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	49,000
Avg Vol	116,390
Day's Range	N/A - N/A
Shares Out	9.98M
Stochastic %K	41%
Beta	1.29
Analysts	Strong Sell
Price Target	$17.00